Santhera Pharmaceuticals announced that it has received a $246,000 grant from the U.S. Food and Drug Administration (FDA) to support its ongoing Phase 1…
Articles by Margarida Azevedo, MSc
Invitae, which specializes in genetic information, has expanded its neurology and cardiology test offerings by adding 11 new panels for…
Tivorsan’s lead investigational therapy for the treatment of Duchenne muscular dystrophy (DMD) has been granted Orphan Drug Designation by the…
New Drug Applications (NDA) for Marathon’s investigational drug deflazacort have been accepted for filing and granted Priority Review by the…
The first patients have been dosed in PhaseBio Pharmaceuticals‘ part one of a Phase 2a clinical trial for PB1046, a once-weekly vasoactive…
The Muscular Dystrophy Association (MDA) and the International Association of Fire Fighters (IAFF) are joining forces this summer…
The Child Neurology Foundation (CNF) recently published a statement in the journal Neurology to address the role of neurologists in transferring…
The National Institute for Health and Care Excellence (NICE) has just issued new guidance recommending Translarna (ataluren) for children older…
Duchenne UK is launching a new video fundraising and awareness campaign for Duchenne muscular dystrophy (DMD) called ‘The…
For the third consecutive year, the Muscular Dystrophy Association‘s nationwide endurance program, the MDA Team Momentum, is revving to run in the…